Spranger Lab researchers describe how a subset of immune cells known as type-2 conventional dendritic cells (DC2) cloak themselves in cancer-associated proteins to provoke an immune response against tumors. Their findings, published in Immunity, indicate that these stealthy operations are driven by the signaling molecule type-1 interferon, suggesting new strategies for targeted immunotherapy.